Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

autophagy

ESMO’s New Focus on Cancer Prevention

During ESMO 2022 in Paris, John Whyte, chief medical officer at WebMD was joined by Fabrice André, MD, PhD, Chair of the scientific committee at the European Society for Medical Oncology (ESMO),...

Medscape Education Global

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

- PMLiVE

AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza

The treatments are for use in prostate, biliary tract and advanced gastric cancer

- PMLiVE

New T-cell study demonstrates ‘powerful’ potential for tailored cancer medicine

The results were published in a peer-reviewed paper in Nature

ESMO Patient Centricity Highlights from Dr. Whyte

During #ESMO22 we brought together a panel of world-renowned experts, including WebMD CMO John Whyte, Professor Nadia Harbeck, MD, PhD, Lesley Fallowfield DBE, and Steve Clark, patient advocate and campaigns ambassador, Cancer Research UK (CRUK), volunteer...

Medscape Education Global

regeneron headquarters

Regeneron’s Libtayo combination granted FDA approval for non-small-cell lung cancer

The decision was based on superior survival outcomes of Libtayo plus chemotherapy

Kaleido – Diabetes Explainer Video

The BriefTo create an engaging administration video for an insulin pump to appeal to a younger and more active generation.The SolutionOur proposed execution included a dynamic lifestyle studio shoot combined...

The Good Ideas Group

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

Eli Lilly set to launch Tempo Personalized Diabetes Management Platform

Users can use the app to log insulin doses, set reminders and access education resources

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

NHS reports rise in prostate cancer treatments in England

Prostate Cancer UK’s risk checker has been used over a million times since its launch in February

- PMLiVE

AbbVie submits application for lymphoma therapy epcoritamab to EMA

Phase 2 trial showed an overall response rate of 63% and a complete response rate of 39%

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links